Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

BACKGROUND: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukem...

Descripción completa

Detalles Bibliográficos
Autores principales: Kampa-Schittenhelm, Kerstin Maria, Heinrich, Michael Charles, Akmut, Figen, Döhner, Hartmut, Döhner, Konstanze, Schittenhelm, Marcus Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637582/
https://www.ncbi.nlm.nih.gov/pubmed/23497317
http://dx.doi.org/10.1186/1476-4598-12-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637582/
https://www.ncbi.nlm.nih.gov/pubmed/23497317
http://dx.doi.org/10.1186/1476-4598-12-19

Ejemplares similares